As both CBP and DOT1L inhibitors are under development for clinical use [59, 60], our study indicates that inhibiting ATM alone or combined with inhibitors targeting CBP or DOT1L would be an advanced approach for treating MLLr-AML. The gene discussed is DOT1L; the disease is acute myeloid leukemia.